Renee Aguiar-Lucander, Calliditas CEO
December 16, 2021 07:11 AM ESTUpdated 10:05 AM
FDA+

Cal­lid­i­tas nabs ac­cel­er­at­ed OK for rare kid­ney dis­ease, beat­ing two com­peti­tors to the punch

Max Gelman

Senior Editor

Since its found­ing, Cal­lid­i­tas has wa­gered it could bring to mar­ket a new for­mu­la­tion of an oral steroid to treat a rare kid­ney dis­ease. And …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

Bio­haven's myo­statin in­hibitor miss­es pri­ma­ry end­point in spinal mus­cu­lar at­ro­phy tri­al

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Gilead buys ex­per­i­men­tal HIV vac­cines from a small Barcelona biotech

A service from the Financial Times